Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25208702 | 0.83 | PIN1 (0.47) | MAPTLMNAALDH1A1KDM4EPKM | |
| SCHEMBL6370147 | 0.77 | LMNA (0.49) | MAPTRAB9AHTTLMNAALDH1A1 | |
| SCHEMBL8887345 | 0.77 | LMNA (0.49) | MAPTRAB9AHTTLMNAALDH1A1 | |
| SCHEMBL11835695 | 0.75 | MAPT (0.53) | MAPTRAB9AHTTLMNAALDH1A1 | |
| SCHEMBL10702301 | 0.75 | MAPT (0.51) | MAPTRAB9ALMNAALDH1A1KMT2A | |
| SCHEMBL22604633 | 0.75 | MERTK (0.56) | MAPTRAB9AHTTLMNAALDH1A1 | |
| SCHEMBL15881241 | 0.75 | SMN1; SMN2 (0.41) | MAPTHTTLMNAALDH1A1GAA | |
| SCHEMBL30749766 | 0.74 | TSHR (0.43) | MAPTALDH1A1GAASMN1; SMN2MAPK1 | |
| SCHEMBL2669593 | 0.74 | TSHR (0.43) | MAPTALDH1A1GAASMN1; SMN2MAPK1 | |
| SCHEMBL22604624 | 0.74 | PIN1 (0.55) | MAPTLMNAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| US-11970486-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-30 | — | — | US | disclosed |
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-18 | — | — | US | disclosed |
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-3700934-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| EP-3529245-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | MAPT 22/4885RAB9A 2129/4885HTT 6/4885 |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | MAPT 22/4885RAB9A 2129/4885HTT 6/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MAPT 22/4885RAB9A 2129/4885HTT 6/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | MAPT 22/4885RAB9A 2129/4885HTT 6/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MAPT 22/4885RAB9A 2129/4885HTT 6/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | MAPT 22/4885RAB9A 2129/4885HTT 6/4885 |
| US-11970486-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MAPT 22/4885RAB9A 2129/4885HTT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.